Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solubilised benzoyl peroxide - Obagi Medical Products

Drug Profile

Solubilised benzoyl peroxide - Obagi Medical Products

Alternative Names: CLENZIderm M.D.; SoluCLENZ Rx Gel; SoluZyl Technology

Latest Information Update: 17 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Obagi Medical Products
  • Class Anti-infectives; Anti-inflammatories; Antiacnes; Benzoic acids; Oxidants; Peroxides; Skin disorder therapies; Small molecules
  • Mechanism of Action Keratinocyte inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 25 Apr 2013 Obagi Medical Products has been acquired by Valeant Pharmaceuticals International
  • 07 Mar 2009 Efficacy data from a clinical trial in Acne released by Obagi Medical Products
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top